NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Inclusion Criteria: * Target population is unresectable stage III (III A-bulky N2, III B) NSCLC with EGFR activating mutation in exon 19 or 21 * Written informed consent provided * Aged 18-75 years * Able to comply with the required protocol and follow-up procedures * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Had a life expectancy of 12 weeks or more * Adequate hematological function, liver function and renal function * Female participants should not be pregnant or breast-feeding Exclusion Criteria: * Known severe hypersensitivity to gefitinib or any of the excipients of this product * Inability to comply with protocol or study procedures * Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab) * Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder * Interstitial pneumonia * Eye inflammation not fully controlled or conditions predisposing the subject to this * Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease) * Known human immunodeficiency virus (HIV) infection * Pregnancy or breast-feeding women * History of neurologic or psychiatric disorders * Ingredients mixed with small cell lung cancer patients